Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 84 of 84 results for infliximab

  1. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    22 October 2007

  2. The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)

    This guidance has been updated and replaced by NICE technology appraisal guidance 187.

    Technology appraisal guidance
    Published
    26 April 2002

  3. Obinutuzumab for untreated advanced follicular lymphoma (TA513)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA513

  4. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  5. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA460

  6. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    27 March 2002

  7. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA419

  8. Research recommendations

    effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for...

  9. NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis

    Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today

    News
    Published
    10 June 2021